Covered recipient · General Payments record
ASHKAN LASHKARI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$42,152.16
- Reported across 344 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,245.00 | 2 |
| Food and Beverage | $1,402.69 | 42 |
| Long term medical supply or device loan | $99.70 | 1 |
| Travel and Lodging | $17.37 | 1 |
| Education | $16.40 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $3,562.37 | 3 |
| BeiGene USA, Inc. | $1,950.00 | 1 |
| PharmaEssentia USA Corporation | $181.99 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $143.26 | 3 |
| Incyte Corporation | $83.56 | 3 |
| EMD Serono, Inc. | $78.65 | 3 |
| Acerta Pharma LLC | $73.77 | 3 |
| Regeneron Healthcare Solutions, Inc. | $69.62 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $67.83 | 3 |
| Genentech USA, Inc. | $63.61 | 2 |
| ADC Therapeutics America, Inc. | $63.32 | 2 |
| Astellas Pharma US Inc | $53.09 | 2 |
| Celgene Corporation | $41.33 | 2 |
| EISAI INC. | $36.31 | 2 |
| Deciphera Pharmaceuticals Inc. | $35.16 | 2 |
| Immunocore Limited | $35.10 | 1 |
| SpringWorks Therapeutics, Inc. | $32.63 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $31.94 | 1 |
| Agios Pharmaceuticals, Inc. | $27.84 | 1 |
| E.R. Squibb & Sons, L.L.C. | $27.10 | 1 |
| PFIZER INC. | $26.80 | 1 |
| Janssen Biotech, Inc. | $22.27 | 1 |
| Pharmacosmos Therapeutics Inc. | $21.67 | 1 |
| AVEO Pharmaceuticals, Inc. | $21.32 | 1 |
| ARRAY BIOPHARMA INC | $15.77 | 1 |
| Gilead Sciences, Inc. | $14.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (47)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.